Krystal Biotech reported a strong Q2 2026 with earnings per share of $1.79, beating analyst estimates and up from $1.29 last year. Revenue grew 24% year-over-year to $119.22 million, mainly due to global sales of its gene therapy VYJUVEK for dystrophic epidermolysis bullosa. The company has secured over 730 U.S. reimbursement approvals, supporting patient access and financial stability. With over $1.1 billion in cash and a very low debt ratio, Krystal Biotech is well-positioned for continued growth in rare disease treatments.
A class action lawsuit has been filed against Capricor Therapeutics and some of its officers for allegedly making false statements about FDA approval risks related to their drug Deramiocel. The complaint claims Capricor changed its clinical data anal...
James Altucher highlights Elon Musk's upcoming project, dubbed "A.R.M.", which Musk claims could generate $25 trillion in new wealth—more than the combined economies of China, Russia, and England. This figure also exceeds the combined market value of...
Diamondback Energy is expected to report a 127.7% jump in Q3 2026 earnings per share to $6.08 and a 31.1% rise in revenue to $4.82 billion, driven by robust oil production and efficiency improvements from advanced drilling technologies. Despite a rec...
MannyPay Global Inc., chaired by Manny Pacquiao, has launched a global payment facilitator platform in partnership with iMerchant and powered by Adyen. The platform supports merchants across more than 70 countries and 135 currencies with features lik...
KKR has agreed to acquire Integer Holdings Corporation, a medical-device outsourcing company, for approximately $5.7 billion at $127 per share. This offer represents a 51.8% premium over Integer's closing price on April 29, 2026, and a 28.8% premium ...
